
Claudia R Morris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/487702/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vasoâ€occlusive pain: A randomized <scp>placeboâ€controlled</scp> trial in progress. American Journal of Hematology, 2022, 97, .	2.0	6
2	Pediatric firearm and motor vehicle collision injuries in the United States: Diverging trends. American Journal of Emergency Medicine, 2022, 53, 59-62.	0.7	4
3	Outcomes of SARS-CoV-2–Positive Youths Tested in Emergency Departments. JAMA Network Open, 2022, 5, e2142322.	2.8	35
4	Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study. Complementary Therapies in Medicine, 2022, 64, 102803.	1.3	5
5	Predictive Value of Isolated Symptoms for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children Tested During Peak Circulation of the Delta Variant. Clinical Infectious Diseases, 2022, 75, 1131-1139.	2.9	1
6	Arginine Therapy and Cardiopulmonary Hemodynamics in Hospitalized Children with Sickle Cell Anemia: A Prospective, Double-blinded, Randomized Placebo-controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 70-80.	2.5	8
7	The Development and Acceptability of a Comprehensive Crisis Prevention Program for Implementation in Health Care Settings. Journal of the American Psychiatric Nurses Association, 2022, , 107839032210935.	0.4	1
8	The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells. Complementary Therapies in Medicine, 2022, 70, 102856.	1.3	3
9	The Relationship Between Parents' Reported Storage of Firearms and Their Children's Perceived Access to Firearms: A Safety Disconnect. Clinical Pediatrics, 2021, 60, 42-49.	0.4	9
10	Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in <scp>Nigeria</scp> . American Journal of Hematology, 2021, 96, 89-97.	2.0	23
11	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	3.8	24
12	Comparison of cost and resource utilization between firearm injuries and motor vehicle collisions at pediatric hospitals. Academic Emergency Medicine, 2021, 28, 630-638.	0.8	7
13	Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers. International Journal of Infectious Diseases, 2021, 105, 474-481.	1.5	6
14	A multicenter evaluation of viral bloodstream detections in children presenting to the Emergency Department with suspected systemic infection. BMC Pediatrics, 2021, 21, 238.	0.7	0
15	Altered amino acid profile in patients with SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	68
16	Reply to Letter to the Editor regarding hospital-based triage travel screens during the COVID-19 pandemic. International Journal of Infectious Diseases, 2021, 107, 165.	1.5	0
17	Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells. Frontiers in Immunology, 2021, 12, 695972.	2.2	50
18	Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C). Experimental Biology and Medicine, 2021, 246, 2543-2552.	1.1	20

#	Article	IF	CITATIONS
19	The need for new test verification and regulatory support for innovative diagnostics. Nature Biotechnology, 2021, 39, 1060-1062.	9.4	2
20	Targeted Proteomics of Pulmonary Hypertension in Sickle Cell Disease. Blood, 2021, 138, 981-981.	0.6	0
21	What is the future of patient-reported outcomes in sickle-cell disease?. Expert Review of Hematology, 2020, 13, 1165-1173.	1.0	10
22	Unique Needs for the Implementation of Emergency Department Human Immunodeficiency Virus Screening in Adolescents. Academic Emergency Medicine, 2020, 27, 984-994.	0.8	3
23	Asymptomatic Adolescent HIV: Identifying a Role for Universal HIV Screening in the Pediatric Emergency Department. AIDS Patient Care and STDs, 2020, 34, 373-379.	1.1	13
24	Utility of Point-of-Care Lung Ultrasonography for Evaluating Acute Chest Syndrome in Young Patients With Sickle Cell Disease. Annals of Emergency Medicine, 2020, 76, S46-S55.	0.3	4
25	Upward Trends of Parotitis and Mumps in Atlanta over a Decade. Global Pediatric Health, 2020, 7, 2333794X2096867.	0.3	Ο
26	Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood, 2020, 136, 1402-1406.	0.6	26
27	Latent Class Analysis of School-Age Children at Risk for Asthma Exacerbation. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2275-2284.e2.	2.0	16
28	Assessment of Cerebral Blood Flow and Oxygen Extraction in Pediatric Sickle Cell Disease with Non-Invasive Diffuse Optical Spectroscopies. Blood, 2020, 136, 7-8.	0.6	1
29	Impact of Oral Arginine Therapy on Global Arginine Bioavailability in Nigerian Children with Sickle Cell Anemia and Vaso-Occlusive Pain. Blood, 2020, 136, 22-23.	0.6	1
30	Acceptability and Barriers to HIV Pre-Exposure Prophylaxis in Atlanta's Adolescents and Their Parents. AIDS Patient Care and STDs, 2019, 33, 425-433.	1.1	14
31	Validation of a composite vascular highâ€risk profile for adult patients with sickle cell disease. American Journal of Hematology, 2019, 94, E312-E314.	2.0	3
32	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	1.5	33
33	Resolution of Acute Priapism in Two Children With Sickle Cell Disease Who Received Nitrous Oxide. Academic Emergency Medicine, 2019, 26, 1102-1105.	0.8	2
34	Do Our Adolescents Know They Are Cyberbullying Victims?. Journal of Infant, Child, and Adolescent Psychotherapy, 2019, 18, 93-101.	0.4	4
35	Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vasoâ€occlusive pain. American Journal of Hematology, 2019, 94, 689-696.	2.0	17
36	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances, 2019, 3, 4002-4020.	2.5	21

#	Article	IF	CITATIONS
37	Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress. Blood, 2019, 134, 995-995.	0.6	1
38	Glutathione and arginine levels: Predictors for acetaminophen-associated asthma exacerbation?. Journal of Allergy and Clinical Immunology, 2018, 142, 308-311.e9.	1.5	3
39	Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vasoâ€occlusive pain: A single institution experience. Pediatric Blood and Cancer, 2018, 65, e26742.	0.8	11
40	Impact of intranasal fentanyl in nurse initiated protocols for sickle cell vasoâ€occlusive pain episodes in a pediatric emergency department. American Journal of Hematology, 2018, 93, E205.	2.0	12
41	Characteristics of Children and Adolescents Diagnosed With <scp>HIV</scp> By Targeted and Diagnostic Testing in a Children's Hospital Network. Academic Emergency Medicine, 2018, 25, 1306-1309.	0.8	7
42	Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine. Nutrition in Clinical Practice, 2017, 32, 30S-47S.	1.1	110
43	Protein Requirements of the Critically III Pediatric Patient. Nutrition in Clinical Practice, 2017, 32, 128S-141S.	1.1	26
44	Assessment of Protein Turnover in Health and Disease. Nutrition in Clinical Practice, 2017, 32, 15S-20S.	1.1	6
45	Summary Points and Consensus Recommendations From the International Protein Summit. Nutrition in Clinical Practice, 2017, 32, 142S-151S.	1.1	75
46	Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention. Expert Review of Hematology, 2017, 10, 875-890.	1.0	9
47	Arginine Therapy Shows Promise for Treatment of Sickle Cell Disease Clinical Subphenotypes of Hemolysis and Arginine Deficiency. Anesthesia and Analgesia, 2017, 124, 1369-1370.	1.1	4
48	l-Arginine Therapy in Sickle Cell Disease. , 2017, , 497-512.		0
49	The Defective Arginine-Nitric Oxide Pathway in Sickle Cell Disease. , 2017, , 355-371.		Ο
50	The role of the arginine metabolome in pain: implications for sickle cell disease. Journal of Pain Research, 2016, 9, 167.	0.8	29
51	Acceptability and Barriers to Pre-exposure Prophylaxis (PrEP) in Atlanta's Adolescents and Their Parents. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
52	Are we missing the mark? Fever, respiratory symptoms, chest radiographs, and acute chest syndrome in sickle cell disease. American Journal of Hematology, 2016, 91, E332-3.	2.0	4
53	Are Subpleural Consolidations on Lung Ultrasound Early Findings of Acute Chest Syndrome?. Blood, 2016, 128, 4869-4869.	0.6	0
54	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	1.2	22

#	Article	IF	CITATIONS
55	Poor Sensitivity of Physician Assessment to Predict Acute Chest Syndrome in Children with Sickle Cell Disease and Fever. Blood, 2015, 126, 2185-2185.	0.6	0
56	Alterations of the Arginine Metabolome in Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2014, 28, 301-321.	0.9	45
57	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	2.5	197
58	Response to "Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18 Haematologica, 2014, 99, e19-e19.	1.7	1
59	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	1.1	107
60	The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions. PLoS ONE, 2014, 9, e101626.	1.1	28
61	More Rapid Delivery of Parenteral Analgesia By Adding Intranasal Fentanyl to the Management of Sickle Cell Disease Vaso-Occlusive Pain Episodes at a Pediatric Emergency Department. Blood, 2014, 124, 4083-4083.	0.6	Ο
62	A Quality Improvement Initiative to Improve Emergency Department Care for Pediatric Patients with Sickle Cell Disease. Journal of Clinical Outcomes Management, 2014, 21, 62-70.	1.7	7
63	Arginine and Asthma. Nestle Nutrition Institute Workshop Series, 2013, 77, 1-15.	1.5	12
64	A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica, 2013, 98, 1375-1382.	1.7	130
65	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367.	1.7	40
66	Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. Blood, 2013, 122, 4690-4690.	0.6	0
67	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	0.6	2
68	Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better! Blood, 2012, 120, 2101-2101.	0.6	3
69	Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom. Blood, 2012, 120, 3240-3240.	0.6	1
70	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network Blood, 2012, 120, 2122-2122.	0.6	1
71	Tricuspid Regurgitant Jet Velocity (TRV), Biomarkers of Hemolysis, and Impact of Oxygen Therapy in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE). Blood, 2012, 120, 4752-4752.	0.6	0
72	Asthma in Sickle Cell Disease. Scientific World Journal, The, 2011, 11, 1138-1152.	0.8	24

#	Article	IF	CITATIONS
73	Arginase and Arginine Dysregulation in Asthma. Journal of Allergy, 2011, 2011, 1-12.	0.7	37
74	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 2011, 118, 855-864.	0.6	210
75	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood, 2011, 118, 3794-3802.	0.6	55
76	Vascular risk assessment in patients with sickle cell disease. Haematologica, 2011, 96, 1-5.	1.7	60
77	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124
78	NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. Blood, 2011, 118, 2125-2125.	0.6	11
79	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. Blood, 2011, 118, 1074-1074.	0.6	1
80	Pulmonary hypertension and NO in sickle cell. Blood, 2010, 116, 852-854.	0.6	59
81	Pulmonary hypertension in thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 205-213.	1.8	61
82	Metabolic Fate of Oral Glutamine Supplementation within Plasma and Erythrocytes of Patients with Sickle Cell Disease: Preliminary Pharmacokinetics Results. Blood, 2010, 116, 1636-1636.	0.6	5
83	Role of Arginase in Sickle Cell Lung Disease and Hemolytic Anemias~!2009-11-12~!2010-03-16~!2010-05-04~!. The Open Nitric Oxide Journal, 2010, 2, 41-54.	0.4	6
84	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 1639-1639.	0.6	0
85	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 947-947.	0.6	1
86	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood, 2010, 116, 2658-2658.	0.6	0
87	Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. Blood, 2010, 116, 4804-4804.	0.6	Ο
88	Hematologic, biochemical, and cardiopulmonary effects of <scp>l</scp> â€arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. European Journal of Haematology, 2009, 82, 315-321.	1.1	58
89	Asthma management: Reinventing the wheel in sickle cell disease. American Journal of Hematology, 2009, 84, 234-241.	2.0	91
90	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study Blood, 2009, 114, 2016-2016.	0.6	3

#	Article	IF	CITATIONS
91	Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial Blood, 2009, 114, 571-571.	0.6	13
92	Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease Blood, 2009, 114, 573-573.	0.6	5
93	Syndrome of allergy, apraxia, and malabsorption: characterization of a neurodevelopmental phenotype that responds to omega 3 and vitamin E supplementation. Alternative Therapies in Health and Medicine, 2009, 15, 34-43.	0.0	8
94	Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. British Journal of Haematology, 2008, 140, 104-112.	1.2	50
95	Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood, 2008, 111, 402-410.	0.6	157
96	Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia. Hematology American Society of Hematology Education Program, 2008, 2008, 177-185.	0.9	146
97	Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders. Current Molecular Medicine, 2008, 8, 620-632.	0.6	95
98	Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway. Current Hypertension Reviews, 2007, 3, 223-230.	0.5	5
99	Clinical hemoglobinopathies: iron, lungs and new blood. Current Opinion in Internal Medicine, 2007, 6, 60-71.	1.5	22
100	Pulmonary Hypertension in Thalassemia: Association with Hemolysis, Arginine Metabolism Dysregulation, and a Hypercoagulable State. Advances in Pulmonary Hypertension, 2007, 6, 31-38.	0.1	10
101	Low Erythrocyte Clutamine-to-Clutamate Ratio: A Novel Biomarker of Hemolysis and Pulmonary Hypertension in Sickle Cell Disease Blood, 2007, 110, 2257-2257.	0.6	0
102	High Frequency of Asthma, Sepsis and Acute Chest Syndrome in Children with Sickle Cell Disease and Pulmonary Hypertension Blood, 2007, 110, 3782-3782.	0.6	0
103	New Strategies for the Treatment of Pulmonary Hypertension in Sickle Cell Disease. Treatments in Respiratory Medicine, 2006, 5, 31-45.	1.4	42
104	Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 2006, 107, 2279-2285.	0.6	561
105	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension Blood, 2006, 108, 1208-1208.	0.6	7
106	Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease Blood, 2006, 108, 788-788.	0.6	1
107	Hemolysis-Associated Pulmonary Hypertension in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 481-485.	1.8	96
108	Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2005, 294, 81.	3.8	619

#	Article	IF	CITATIONS
109	Abnormal Pulmonary Function in Adults and Children with Sickle Cell Disease Blood, 2005, 106, 2319-2319.	0.6	1
110	Dysregulated Arginine Metabolism and Elevated Arginase Activity in Thalassemia Blood, 2005, 106, 3644-3644.	0.6	0
111	Elevated Plasma Arginase Levels in Hemoglobinopathies Blood, 2005, 106, 2346-2346.	0.6	1
112	Decreased Arginine Bioavailability and Increased Serum Arginase Activity in Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 148-153.	2.5	252
113	Pulmonary Hypertension in Sickle Cell Disease: A Common Complication for Both Adults and Children Blood, 2004, 104, 1666-1666.	0.6	1
114	The Arginine-to-Ornithine Ratio: Biomarker of Arginase Activity and Predictor of Mortality in Sickle Cell Disease Blood, 2004, 104, 237-237.	0.6	6
115	Pulmonary Hypertension: A Common Complication in Thalassemia Blood, 2004, 104, 3612-3612.	0.6	0
116	l -arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. British Journal of Haematology, 2003, 120, 532-534.	1.2	55
117	Arginine Therapy. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 63-69.	2.5	302
118	Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2003, 25, 629-634.	0.3	79
119	Patterns of Arginine and Nitric Oxide in Patients With Sickle Cell Disease With Vaso-occlusive Crisis and Acute Chest Syndrome. The American Journal of Pediatric Hematology/oncology, 2000, 22, 515-520.	1.3	176
120	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. British Journal of Haematology, 2000, 111, 498-500.	1.2	38
121	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. SHORT REPORT. British Journal of Haematology, 2000, 111, 498-500.	1.2	102